While a more effective monoclonal antibody competitor for the breast cancer drug Rituxan is under development, and major trials are underway of an experimental drug that may be more effective than Tamoxifen at preventing breast cancer, there’s not so promising news of Tarceva, which failed to increase overall lung cancer survival rates in recently concluded […]